Eli Lilly appoints Vineet Gupta as the General Manager adgully.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from adgully.com Daily Mail and Mail on Sunday newspapers.
Coronavirus | Eli Lilly India combination gets nod for emergency use
Updated:
Updated:
It could be used for treatment of mild to moderate COVID-19
Share Article
AAA
Eli Lilly and Company India on Tuesday said it has received permission for emergency use of its antibody drugs combination used for treatment of mild to moderate COVID-19.
| Photo Credit:
REUTERS
It could be used for treatment of mild to moderate COVID-19
Eli Lilly and Company India on Tuesday said it has received permission for emergency use of its antibody drugs combination used for treatment of mild to moderate COVID-19.
The company has received permission for restricted emergency use of its monoclonal antibody drugs, bamlanivimab 700 mg and etesevimab 1400 mg, used together for the treatment, it said in a statement.
India Diabetes Care Market Competition, Forecast & Opportunities, 2027
News provided by
Share this article
Share this article
ResearchAndMarkets.com s offering.
The Indian Diabetes Care Market was valued at USD1530.3 million in value terms in FY2020 and is forecast to grow at CAGR of 7.94% in value terms to reach USD2408.39 million by FY2026.
The Indian Diabetes Care Market is witnessing consistent growth, owing to the increasing geriatric population, increasing diabetic population and the adoption of an unhealthy lifestyle leading to obesity that further increases the diabetic population. Moreover, factors such as advancing technology and increasing cost of living are continuously fueling the diabetes care market in India.